Breckenridge Pharmaceutical, Inc. Announces Acquisition of 5 ANDA's

Tuesday, October 3, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

BOCA RATON, Fla., Oct. 3, 2017 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced today it has acquired five

(5) Abbreviated New Drug Applications from Nostrum Laboratories Inc., a wholly owned subsidiary of Nostrum Pharmaceuticals, LLC.  Three of the acquired assets are FDA approved and will be sold by Breckenridge under its label. Two of the assets are filed
and pending with FDA with anticipated approval dates within the next 12 months. The total generic market value for these products is $305 Million, according to July 2017 IMS data.

The three approved ANDAs are CNS products indicted for the treatment of Attention Deficit Disorders and Narcolepsy Attention Deficit Disorders in various dosage forms.

The parties have entered into a separate agreement whereby Nostrum will remain the exclusive manufacturer for certain assets.

About Breckenridge:Breckenridge Pharmaceutical, Inc. is a privately-held own-label distributor that performs pharmaceutical marketing, research and development, as well as marketing and distribution in the U.S. The company was founded in 1983 and markets a broad range of generic prescription products in many therapeutic categories. The Breckenridge label is recognized by wholesalers, distributors, chains, and managed care accounts, as well as retail pharmacies nationwide. The company markets over 70 products in a variety of dosage forms including: tablets, capsules, soft gel capsules, liquids, suspensions, ophthalmics, nasal sprays, powders and injectable products. www.bpirx.com

About Nostrum:Nostrum Laboratories, Inc. is a wholly owned subsidiary of Nostrum Pharmaceuticals, LLC principally engaged in the development, manufacture and commercialization of specialty pharmaceutical products and controlled release orally administered generic drugs utilizing its proprietary controlled release drug delivery technologies.

View original content:http://www.prnewswire.com/news-releases/breckenridge-pharmaceutical-inc-announces-acquisition-of-5-andas-300530024.html

SOURCE Breckenridge Pharmaceutical, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Find a Doctor
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook